Associations of soluble CD14 and endotoxin with mortality, cardiovascular disease, and progression of kidney disease among patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 9, 2015, Pages 1525-1533

  Poesen, Ruben ^a   Ramezani, Ali ^b   Claes, Kathleen ^a   Augustijns, Patrick ^c   Kuypers, Dirk ^a   Barrows, Ian R ^d   Muralidharan, Jagadeesan ^b   Evenepoel, Pieter ^a   Meijers, Björn ^a   Raj, Dominic S ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CREATININE; ENDOTOXIN; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; BLOOD SAMPLING; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; LIMULUS LYSATE TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITION; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR; AGED; BELGIUM; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX;

AGED; ANTIGENS, CD14; BELGIUM; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; ENDOTOXINS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84941219621     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03100315     Document Type: Article

References (42)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004
2. Berg RD: The indigenous gastrointestinal microflora. Trends Microbiol 4: 430–435, 1996
3. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, Desantis TZ, Ni Z, Nguyen TH, Andersen GL: Chronic kidney disease alters intestinal microbial flora. Kidney Int 83: 308–315, 2013
4. Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS: Disintegration of colonic epithelial tight junction in uremia: A likely cause of CKD-associated inflammation. Nephrol Dial Transplant 27: 2686–2693, 2012
5. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T: Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32: 754–759, 1991
6. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: Prospective results from the Bruneck Study. J Am Coll Cardiol 34: 1975–1981, 1999
7. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, Li PK: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin JAmSoc Nephrol 3: 431–436, 2008
8. Miyake K: Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12: 186–192, 2004
9. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 1431–1433, 1990
10. Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13: 437–457, 1995
11. Hailman E, Vasselon T, Kelley M, Busse LA, Hu MC, Lichenstein HS, Detmers PA, Wright SD: Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J Immunol 156: 4384–4390, 1996
12. Pugin J, Schürer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS: Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A 90: 2744–2748, 1993
13. Schütt C, Schilling T, Grunwald U, Schönfeld W, Krüger C: Endotoxin-neutralizing capacity of soluble CD14. Res Immunol 143: 71–78, 1992
14. Raj DS, Carrero JJ, Shah VO, Qureshi AR, Bárány P, Heimbürger O, Lindholm B, Ferguson J, Moseley PL, Stenvinkel P: Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis 54: 1072–1080, 2009
15. Raj DS, Shah VO, Rambod M, Kovesdy CP, Kalantar-Zadeh K: Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 54: 1062–1071, 2009
16. Coulliette AD, Arduino MJ: Hemodialysis and water quality. Semin Dial 26: 427–438, 2013
17. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P: p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5: 1182–1189, 2010
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
19. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ: CD14 is a pattern recognition receptor. Immunity 1: 509–516, 1994
20. Erridge C, Attina T, Spickett CM, Webb DJ: A high-fatmeal induces low-grade endotoxemia: Evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86: 1286–1292, 2007
21. Nockher WA, Scherberich JE: Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int 48: 1469–1476, 1995
22. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C: CD14 is an acute-phase protein. J Immunol 172: 4470–4479, 2004
23. Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE, Munford RS: Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 108: 485–493, 2001
24. Bussolati B, David S, Cambi V, Tobias PS, Camussi G: Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS. Int J Mol Med 10: 441–449, 2002
25. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC; INSIGHT SMART Study Group: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780–790, 2011
26. Nisbeth U, Hällgren R, Eriksson O, Danielson BG: Endotoxemia in chronic renal failure. Nephron 45: 93–97, 1987
27. Gonçalves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AE, Lima EG, Fuerbringer R, Sauthier SM, Riella MC: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 21: 2788–2794, 2006
28. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK: Circulating endotoxemia: A novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6: 133–141, 2011
29. Taniguchi T, Katsushima S, Lee K, Hidaka A, Konishi J, Ideguchi H, Kawaguchi Y: Endotoxemia in patients on hemodialysis. Nephron 56: 44–49, 1990
30. Herring WB, Herion JC, Walker RI, Palmer JG: Distribution and clearance of circulating endotoxin. J Clin Invest 42: 79–87, 1963
31. Cohen J: The detection and interpretation of endotoxaemia. Intensive Care Med 26[Suppl 1]: S51–S56, 2000
32. Mattsby-Baltzer I, Lindgren K, Lindholm B, Edebo L: Endotoxin shedding by enterobacteria: Free and cell-bound endotoxin differ in Limulus activity. Infect Immun 59: 689–695, 1991
33. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD: Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392: 505–509, 1998
34. Nockher WA, Wigand R, Schoeppe W, Scherberich JE: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 96: 15–19, 1994
35. Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, Calandra T: Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis 171: 639–644, 1995
36. Zalai CV, Kolodziejczyk MD, Pilarski L, Christov A, Nation PN, Lundstrom-Hobman M, Tymchak W, Dzavik V, Humen DP, Kostuk WJ, Jablonsky G, Pflugfelder PW, Brown JE, Lucas A: Increased circulating monocyte activation in patients with unstable coronary syndromes. J Am Coll Cardiol 38: 1340–1347, 2001
37. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, Drouet L, Ferrières J: Soluble CD14 and aortic stiffness in a population-based study. J Hypertens 21: 1869–1877, 2003
38. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, Walston J, Lange LA, Cushman M, Tracy RP: Soluble CD14: Genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol 33: 158–164, 2013
39. Schrier RW, Wang W: Acute renal failure and sepsis. NEngl J Med 351: 159–169, 2004
40. Morrissey J, Guo G, McCracken R, Tolley T, Klahr S: Induction of CD14 in tubular epithelial cells during kidney disease. J Am Soc Nephrol 11: 1681–1690, 2000
41. Zhou J, Ouyang X, Cui X, Schoeb TR, Smythies LE, Johnson MR, Guay-Woodford LM, Chapman AB, Mrug M: Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int 78: 550–560, 2010
42. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3: 1526–1533, 2008